Literature DB >> 8899249

The effect of risperidone on cognition in patients with schizophrenia.

E Stip1, I Lussier.   

Abstract

OBJECTIVE: To evaluate the effect of risperidone on cognitive functions after both 6 weeks and 6 months of treatment and to determine whether any improvement on neuropsychological function relates to improvement in psychopathology.
METHOD: Patients' psychiatric and extrapyramidal symptoms were assessed while they were receiving classical neuroleptic treatment and adjunctive medications. Patients were then reassessed after changing to a new treatment of risperidone.
RESULTS: During treatment with risperidone, schizophrenic patients displayed improved performance mainly on attentional components, specifically, selective attention and alertness.
CONCLUSION: In patients who were given risperidone, there was a positive correlation between improvement in psychopathology and improvement in cognitive tests of explicit memory and alertness.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899249     DOI: 10.1177/070674379604100802

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  13 in total

Review 1.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications.

Authors:  S E Purdon
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 2.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

Review 3.  Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.

Authors:  Nurith Amitai; Athina Markou
Journal:  Biol Psychiatry       Date:  2010-05-21       Impact factor: 13.382

4.  Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function.

Authors:  Garry D Honey; Edith Pomarol-Clotet; Philip R Corlett; Rebekah A E Honey; Peter J McKenna; Edward T Bullmore; Paul C Fletcher
Journal:  Brain       Date:  2005-09-23       Impact factor: 13.501

Review 5.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 6.  WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia.

Authors:  Simon Gilbody; Anne-Marie Bagnall; Lorna Duggan; Arja Tuunainen
Journal:  Cochrane Database Syst Rev       Date:  2016-09-20

Review 7.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 8.  Treatment of schizophrenia and delusional disorder in the elderly.

Authors:  J H Eastham; D V Jeste
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 9.  Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms.

Authors:  Michael A Cirillo; Larry J Seidman
Journal:  Neuropsychol Rev       Date:  2003-06       Impact factor: 7.444

10.  Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task.

Authors:  Vera Bubenikova-Valesova; Ales Stuchlik; Jan Svoboda; Jan Bures; Karel Vales
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.